TY - JOUR
T1 - Cardiac impact of dapagliflozin in advanced chronic kidney disease
T2 - rationale and design of the Renal Lifecycle Trial cardiac imaging sub-studies
AU - Karsten, Micky
AU - Badve, Sunil V.
AU - Renal Lifecycle Trial Cardiac Imaging Sub-studies Investigators
AU - Gansevoort, Ron T.
AU - Berger, Stefan P.
AU - Heerspink, Hiddo J.L.
AU - Abrahams, Alferso C.
AU - Billot, Laurent
AU - Bon, Rianne H.A.C.M.
AU - Gelens, Mariëlle A.C.J.
AU - Guinness, Dean
AU - Hamilton-Craig, Christian
AU - van Heerebeek, Loek
AU - Hemmelder, Marc H.
AU - Houston, Lauren
AU - Kozor, Rebecca
AU - Kuypers, Dirk R.J.
AU - Monaghan, Helen
AU - Neal, Bruce
AU - Neuen, Brendon L.
AU - Otton, James
AU - Perkovic, Vlado
AU - Rajwani, Adil
AU - Wang, Angela Y.
AU - Vervloet, Marc G.
AU - Arnott, Clare
AU - Jakulj, Lily
AU - van Etten, Ronald
AU - Francois, Karlien
AU - Gois, Pedro
AU - van der Heijden, Joost
AU - Holt, Jane
AU - Jesudason, Shilpa
AU - Keung, Karen
AU - Kim, Yu Sok
AU - Krishnasamy, Rathika
AU - Kulkarni, Hemant
AU - van der Leeuw, Joep
AU - Makris, Angela
AU - Masterson, Rosemary
AU - Mather, Amanda
AU - Ocak, Gurbey
AU - Palamuthusingam, Dharmenaan
AU - Pedagogos, Eugenia
AU - Siegert, Carl
AU - Smyth, Brendan
AU - Srivastava, Vikas
AU - Talaulikar, Girish
AU - Vleut, Rowena
AU - Waanders, Femke
AU - Wong, Germaine
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2026/1
Y1 - 2026/1
N2 - Background:Patients with chronic kidney disease (CKD) are frequently hospitalized for heart failure. Sodium-glucose co-transporter 2 (SGLT2)-inhibitors improve cardiorenal outcomes in CKD and heart failure, at least in estimated glomerular filtration rate (eGFR) ranges 20-60 ml/min/1.73 m2, possibly through direct cardiac effects. In the cardiac imaging sub-studies of the Renal Lifecycle Trial, we aim to establish the effects of SGLT2-inhibition on cardiac structure and function in patients with advanced CKD, kidney failure and in kidney transplant recipients.Methods:In the Renal Lifecycle Trial, patients with advanced CKD (eGFR ≤25 ml/min/1.73 m2), those treated with hemodialysis or peritoneal dialysis (PD) or kidney transplant recipients (eGFR ≤45 ml/min/1.73 m2), are randomized to receive either dapagliflozin or placebo. The echocardiography sub-study (acronym: STOP-HF-in-PD) will enroll 100 PD-treated patients, who undergo echocardiography at baseline, and at 6 and 12 months post-randomization. In the cardiac magnetic resonance imaging (MRI) sub-study, 250 Renal Lifecycle Trial participants across all three groups (i.e. advanced CKD, dialysis, kidney transplant recipients), including a subset of STOP-HF-in-PD participants, will undergo cardiac MRI at baseline, and at 12 months post-randomization. The primary endpoint of STOP-HF-in-PD is the difference in left ventricular global longitudinal strain, a measure of cardiac function, after 6-months of dapagliflozin compared to placebo. For the cardiac MRI sub-study, the primary endpoint is the difference of indexed left ventricular mass after 12 months of dapagliflozin compared to placebo. Conclusions:The Renal Lifecycle Trial cardiac imaging sub-studies will generate novel data on the effects of SGLT2-inhibition on cardiac structure and function in a population with advanced CKD, in whom SGLT2-inhibitor induced cardiovascular protection remains to be established.
AB - Background:Patients with chronic kidney disease (CKD) are frequently hospitalized for heart failure. Sodium-glucose co-transporter 2 (SGLT2)-inhibitors improve cardiorenal outcomes in CKD and heart failure, at least in estimated glomerular filtration rate (eGFR) ranges 20-60 ml/min/1.73 m2, possibly through direct cardiac effects. In the cardiac imaging sub-studies of the Renal Lifecycle Trial, we aim to establish the effects of SGLT2-inhibition on cardiac structure and function in patients with advanced CKD, kidney failure and in kidney transplant recipients.Methods:In the Renal Lifecycle Trial, patients with advanced CKD (eGFR ≤25 ml/min/1.73 m2), those treated with hemodialysis or peritoneal dialysis (PD) or kidney transplant recipients (eGFR ≤45 ml/min/1.73 m2), are randomized to receive either dapagliflozin or placebo. The echocardiography sub-study (acronym: STOP-HF-in-PD) will enroll 100 PD-treated patients, who undergo echocardiography at baseline, and at 6 and 12 months post-randomization. In the cardiac magnetic resonance imaging (MRI) sub-study, 250 Renal Lifecycle Trial participants across all three groups (i.e. advanced CKD, dialysis, kidney transplant recipients), including a subset of STOP-HF-in-PD participants, will undergo cardiac MRI at baseline, and at 12 months post-randomization. The primary endpoint of STOP-HF-in-PD is the difference in left ventricular global longitudinal strain, a measure of cardiac function, after 6-months of dapagliflozin compared to placebo. For the cardiac MRI sub-study, the primary endpoint is the difference of indexed left ventricular mass after 12 months of dapagliflozin compared to placebo. Conclusions:The Renal Lifecycle Trial cardiac imaging sub-studies will generate novel data on the effects of SGLT2-inhibition on cardiac structure and function in a population with advanced CKD, in whom SGLT2-inhibitor induced cardiovascular protection remains to be established.
UR - https://www.scopus.com/pages/publications/105027469296
U2 - 10.1093/ckj/sfaf376
DO - 10.1093/ckj/sfaf376
M3 - Article
C2 - 41551843
AN - SCOPUS:105027469296
SN - 2048-8505
VL - 19
JO - Clinical Kidney Journal
JF - Clinical Kidney Journal
IS - 1
M1 - sfaf376
ER -